Skip to content
MARKETS / NASDAQ / BDMD
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Baird Medical Investment Holdings Ltd. BDMD

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$22.5M
▼ 39.2% YoY
$-27.3M
▼ 319.0% YoY
$-1.4M
In brief

What this company does

Our business primarily includes the design, development, manufacturing and sale of our proprietary microwave ablation medical devices and sales of other medical devices. We produce five models of proprietary microwave ablation therapeutic apparatus. We also distribute and sell other medical devices, such as catheters, ventilators, operation tables, medical gloves, syringes, and large medical machines and systems. We ranked first among microwave ablation medical device providers in the treatment of thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of microwave ablation needles in 2022 according to the Frost & Sullivan Report.

Written from the business description in Baird Medical Investment Holdings Ltd's annual report to the U.S. Securities and Exchange Commission, filed 24 April 2026. Every sentence was checked against that document before publication.

Growth
USD 22.5M
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2025 · Revenue 22.5 · Net income -27.3
20M-10M-20M2022202320242025
Compound annual growth
−13.7%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−122 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -113.7% · Net -122.2%
20%40%-50%-100%2022202320242025
ROE
FY2025 · ROE -76.8%
10%20%30%-20%-40%-60%2022202320242025

Each USD of equity lost 77 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -1.4
-4M-8M2022202320242025

Total assetsUSD 69.7M
EquityUSD 31.4M
CashUSD 178,321.00
Gross debtUSD 8.7M
Net debtUSD 8.5M
Current ratio1.70×

Net debt stands at 27% of equity.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022
Revenue $B0.00.00.00.0
Operating income $B−0.00.00.00.0
EBITDA $B−0.00.00.00.0
Income tax $B0.00.00.00.0
Net income $B−0.00.00.00.0
Free cash flow $B−0.0−0.0−0.0−0.0
EPS, diluted $−0.980.570.510.49
Dividend / sh $····
Payout %····
ROE %−76.833.029.5·
Shares out B0.030.030.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 18 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 77 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2022

Share this section

Download image